The global mTOR inhibitors market size was US$ 6,498 million in 2021. The global mTOR inhibitors market size is forecast to reach US$ 9,445 million by 2030, growing at a compound annual growth rate (CAGR) of 4.3% during the forecast period from 2022 to 2030.
The mechanistic target of rapamycin (mTOR) is a serine-threonine protein kinase conserved in the organism. It serves as the immunosuppressive medication rapamycin's target. mTOR is a therapeutic target for disorders like cancer that are brought on by unchecked cell proliferation because it plays a crucial role in regulating cell growth and proliferation. Over the past ten years, various mTOR inhibitors have been developed, and many are currently being tested in clinical settings to treat cancer. mTOR regulates cellular growth, expansion, and metabolism by creating and signaling through the two protein complexes known as mTORC1 and mTORC2. The most well-known mTOR inhibitors are rapalogs (rapamycin and its analogs), which have shown tumor responses in human trials against a number of tumor types.
Factors Influencing Market Growth
Impact Analysis of COVID-19
The COVID-19 pandemic had a negative impact on the global market. The COVID-19 pandemic disrupted routine care in many healthcare facilities and had an impact on the world's healthcare systems, putting at-risk cancer patients at serious risk. An American Society of Clinical Oncology Journal surveyed 356 facilities from 54 countries on six continents between April 21 and May 8, 2020, according to a report from the American Society of Clinical Oncology that was published in September 2020. Every year, these facilities treat 716,979 new cancer patients. The majority (88.2%) claimed to have experienced difficulties providing care throughout the pandemic.
Regional Analysis
North America garnered the major market share in 2021 and is forecast to remain dominant during the forecast period. As a result of the rising healthcare expenditure, the existence of key players, well-establish healthcare facilities, and a growing number of elderly populations.
The Asia Pacific region is forecast to have lucrative growth during the forecast period. As a result of the growing number of cancer patients, increasing government initiatives toward drug development, and rising awareness for novel treatments.
Leading Competitors
The leading prominent companies profiled in the global mTOR inhibitors market are:
Scope of the Report
The global mTOR inhibitors market segmentation focuses on Product Type, Indication, Route of Administration, End-Users, Distribution Channel, and Region.
Segmentation based on Product Type
Segmentation based on Indication
Segmentation based on Route of Administration
Segmentation based on End-Users
Segmentation based on Distribution Channel
Segmentation based on Region
[TABLE OF CONTENTS]
1 INTRODUCTION OF GLOBAL MTOR INHIBITORS MARKET
1.1 OVERVIEW OF THE MARKET
1.2 SCOPE OF REPORT
1.3 ASSUMPTIONS
2 EXECUTIVE SUMMARY
3 RESEARCH METHODOLOGY
3.1 DATA MINING
3.2 VALIDATION
3.3 PRIMARY INTERVIEWS
3.4 LIST OF DATA SOURCES
4 GLOBAL MTOR INHIBITORS MARKET OUTLOOK
4.1 OVERVIEW
4.2 MARKET DYNAMICS
4.2.1 DRIVERS
4.2.2 RESTRAINTS
4.2.3 OPPORTUNITIES
4.3 PORTERS FIVE FORCE MODEL
4.4 VALUE CHAIN ANALYSIS
5 GLOBAL MTOR INHIBITORS MARKET, BY PRODUCT TYPE
5.1 OVERVIEW
5.2 RAPAMUNE
5.3 AFINITOR
5.4 TORISEL
5.5 ZORTRESS
5.6 OTHERS
6 GLOBAL MTOR INHIBITORS MARKET, BY INDICATION
6.1 OVERVIEW
6.2 ONCOLOGY
6.3 ORGAN TRANSPLANTATION
6.4 IMMUNOSUPPRESSANT
6.5 OTHERS
7 GLOBAL MTOR INHIBITORS MARKET, BY ROUTE OF ADMINISTRATION
7.1 OVERVIEW
7.2 ORAL
7.3 INTRAVENOUS
8 GLOBAL MTOR INHIBITORS MARKET, BY END-USERS
8.1 OVERVIEW
8.2 HOSPITALS
8.3 SPECIALTY CLINICS
8.4 OTHERS
9 GLOBAL MTOR INHIBITORS MARKET, BY DISTRIBUTION CHANNEL
9.1 OVERVIEW
9.2 HOSPITAL PHARMACIES
9.3 RETAIL PHARMACIES
9.4 ONLINE PHARMACIES
10 GLOBAL MTOR INHIBITORS MARKET, BY GEOGRAPHY
10.1 OVERVIEW
10.2 NORTH AMERICA
10.2.1 NORTH AMERICA MARKET SNAPSHOT
10.2.2 U.S.
10.2.3 CANADA
10.2.4 MEXICO
10.3 EUROPE
10.3.1 EUROPE MARKET SNAPSHOT
10.3.2 WESTERN EUROPE
10.3.2.1 THE UK
10.3.2.2 GERMANY
10.3.2.3 FRANCE
10.3.2.4 ITALY
10.3.2.5 SPAIN
10.3.2.6 REST OF WESTERN EUROPE
10.3.3 EASTERN EUROPE
10.3.3.1 POLAND
10.3.3.2 RUSSIA
10.3.3.3 REST OF EASTERN EUROPE
10.4 ASIA PACIFIC
10.4.1 ASIA PACIFIC MARKET SNAPSHOT
10.4.2 CHINA
10.4.3 JAPAN
10.4.4 INDIA
10.4.5 AUSTRALIA & NEW ZEALAND
10.4.6 ASEAN
10.4.7 REST OF ASIA PACIFIC
10.5 MIDDLE EAST & AFRICA
10.5.1 MIDDLE EAST & AFRICA MARKET SNAPSHOT
10.5.2 UAE
10.5.3 SAUDI ARABIA
10.5.4 SOUTH AFRICA
10.5.5 REST OF MEA
10.6 SOUTH AMERICA
10.6.1 SOUTH AMERICA MARKET SNAPSHOT
10.6.2 BRAZIL
10.6.3 ARGENTINA
10.6.4 REST OF SOUTH AMERICA
11 GLOBAL MTOR INHIBITORS MARKET COMPETITIVE LANDSCAPE
11.1 OVERVIEW
11.2 COMPANY MARKET RANKING
11.3 KEY DEVELOPMENT STRATEGIES
12 COMPANY PROFILES
12.1 ABBVIE INCORPORATED
12.1.1 OVERVIEW
12.1.2 FINANCIAL PERFORMANCE
12.1.3 PRODUCT OUTLOOK
12.1.4 KEY DEVELOPMENTS
12.2 ACCORD HEALTHCARE
12.2.1 OVERVIEW
12.2.2 FINANCIAL PERFORMANCE
12.2.3 PRODUCT OUTLOOK
12.2.4 KEY DEVELOPMENTS
12.3 ASTRAZENECA
12.3.1 OVERVIEW
12.3.2 FINANCIAL PERFORMANCE
12.3.3 PRODUCT OUTLOOK
12.3.4 KEY DEVELOPMENTS
12.4 BRISTOL-MYERS SQUIBB COMPANY
12.4.1 OVERVIEW
12.4.2 FINANCIAL PERFORMANCE
12.4.3 PRODUCT OUTLOOK
12.4.4 KEY DEVELOPMENTS
12.5 DR. REDDY’S LABORATORIES LIMITED
12.5.1 OVERVIEW
12.5.2 FINANCIAL PERFORMANCE
12.5.3 PRODUCT OUTLOOK
12.5.4 KEY DEVELOPMENTS
12.6 ELI LILLY AND COMPANY
12.6.1 OVERVIEW
12.6.2 FINANCIAL PERFORMANCE
12.6.3 PRODUCT OUTLOOK
12.6.4 KEY DEVELOPMENTS
12.7 HIKMA PHARMACEUTICALS PLC
12.7.1 OVERVIEW
12.7.2 FINANCIAL PERFORMANCE
12.7.3 PRODUCT OUTLOOK
12.7.4 KEY DEVELOPMENTS
12.8. MERCK & CO INCORPORATED
12.8.1 OVERVIEW
12.8.2 FINANCIAL PERFORMANCE
12.8.3 PRODUCT OUTLOOK
12.8.4 KEY DEVELOPMENTS
12.9 NOVARTIS AG, PFIZER INCORPORATED
12.9.1 OVERVIEW
12.9.2 FINANCIAL PERFORMANCE
12.9.3 PRODUCT OUTLOOK
12.9.4 KEY DEVELOPMENTS
12.10 TEVA PHARMACEUTICALS INDUSTRIES LIMITED
12.9.1 OVERVIEW
12.9.2 FINANCIAL PERFORMANCE
12.9.3 PRODUCT OUTLOOK
12.9.4 KEY DEVELOPMENTS
12.11 ZYDUS PHARMACEUTICALS, INCORPORATED
12.9.1 OVERVIEW
12.9.2 FINANCIAL PERFORMANCE
12.9.3 PRODUCT OUTLOOK
12.9.4 KEY DEVELOPMENTS
01
お客様のニーズに合わせてレポートをカスタマイズ可能
02
ベテランの市場調査員による専門的な分析
03
安全で簡単に利用できるオンライン決済方法
04
お客様のご要望に応じて、特定の章を購入することができます。
05
すべてのレポートに専門的な日本語翻訳を提供
06
包括的でわかりやすいレポートを迅速にお届けします。
07
購入後も継続的なサポートとアップデートが受けられます。
We Accept
Copyright ©2022 All rights reserved